Asset Details
Do you wish to reserve the book?
TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy
Do you wish to request the book?
TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy
2020
Overview
Tumor necrosis factor superfamily member 14 (LIGHT) has been in pre-clinical development for over a decade and shows promise as a modality of enhancing treatment approaches in the field of cancer immunotherapy. To date, LIGHT has been used to combat cancer in multiple tumor models where it can be combined with other immunotherapy modalities to clear established solid tumors as well as treat metastatic events. When LIGHT molecules are delivered to or expressed within tumors they cause significant changes in the tumor microenvironment that are primarily driven through vascular normalization and generation of tertiary lymphoid structures. These changes can synergize with methods that induce or support anti-tumor immune responses, such as checkpoint inhibitors and/or tumor vaccines, to greatly improve immunotherapeutic strategies against cancer. While investigators have utilized multiple vectors to LIGHT-up tumor tissues, there are still improvements needed and components to be found within a human tumor microenvironment that may impede translational efforts. This review addresses the current state of this field.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Cancer
/ CD258
/ Cells
/ Glioma
/ Humans
/ Hypoxia
/ Immune checkpoint inhibitors
/ Immunity
/ Kinases
/ LIGHT
/ Melanoma
/ Mice
/ Proteins
/ Tumor Microenvironment - drug effects
/ Tumor Microenvironment - immunology
/ Tumor Necrosis Factor Ligand Superfamily Member 14 - immunology
/ Tumor Necrosis Factor Ligand Superfamily Member 14 - therapeutic use
/ tumor necrosis factor superfamily member 14 (TNFSF14)
/ Tumors
